Luminal tumors, the most frequent (accounting for 50–60% of breast cancers) [5], are associated with the most favorable prognoses, while HER2-overexpressing and triple-negative tumors are associated with worst prognoses [6,7]. The gene discussed is ERBB2; the disease is breast carcinoma.